MAXYGEN INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-11-16: Form 8-K; Period of report 2012-11-15; Description 8.01 Other Events; Details 8.01.
- 2012-11-06: Form 8-K; Period of report 2012-11-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-08-07: Form 8-K; Period of report 2012-08-07; Description 2.02 Results of Operations and Financial Condition; 8.01 Other Events; Details 2.02.
- 2012-06-07: Form 8-K; Period of report 2012-06-06; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-11-16 | 8-K | 2012-11-15 | 8.01 Other Events | 8.01 On November 15, 2012, Board of Directors of Maxygen, Inc. (the “Company” or “Maxygen”) approved the extension of the Company’s current stock repurchase program through December 31, 2013. | d440824d8k.htm |
| 2012-11-06 | 8-K | 2012-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2012, Maxygen, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2012. | d431948d8k.htm |
| 2012-08-07 | 8-K | 2012-08-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 7, 2012, Maxygen, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2012. 8.01 On August 7, 2012, the Company announced a cash distribution of $3.60 per share of its common stock. | d391018d8k.htm |
| 2012-06-07 | 8-K | 2012-06-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Maxygen, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 6, 2012. | d366278d8k.htm |
| 2012-05-14 | 8-K | 2012-05-11 | 8.01 Other Events | 8.01 On May 11, 2012, Maxygen, Inc. (the “Company”) received notice from Bayer HealthCare LLC (“Bayer”) that Bayer had achieved the milestone event under the technology transfer agreement between the parties, dated July 1, 2008, pursuant to which the Company will receive a $30.0 million payment from Bayer. | d352566d8k.htm |
| 2012-05-07 | 8-K | 2012-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2012, Maxygen, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2012. | d348101d8k.htm |
| 2012-03-08 | 8-K | 2012-03-02 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On March 8, 2012, Maxygen, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2011. 5.02 (e) On March 2, 2012, the Compensation Committee of the Company’s Board of the Directors approved the Company’s entry into a change of control agreement with John Borkholder, the Company’s General Counsel and Secretary. | d311579d8k.htm |
| 2012-01-26 | 8-K | 2012-01-26 | 8.01 Other Events | 8.01 In November 2011, Maxygen, Inc. (the “Company”) announced that its proposal for a contract award from the Biomedical Advanced Research and Development Authority, an agency within the U.S. Department of Health and Human Services (“BARDA”), for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (“ARS”) was rejected by BARDA. | d288314d8k.htm |